Business Wire1h
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
FierceBiotech1h
Pfizer’s investigational candidate combo cuts prostate cancer progression by 49% in phase 1
After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” ...
Leerink Partnrs Lowers Earnings Estimates for Q32 Bio
Leerink Partnrs decreased their FY2025 earnings estimates for shares of Q32 Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now ...
GEN17h
Intra-ImmuSG Focuses on Intracellular Targets for Cancer Immunotherapy
Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.